Emerging treatments for lupus nephritis: health equity considerations in clinical research and coverage

J Manag Care Spec Pharm. 2021 Oct;27(10):1500-1502. doi: 10.18553/jmcp.2021.27.10.1500.

Authors

Terri V Newman¹, Jingchuan Guo², Inmaculada Hernandez³

Affiliations

¹ Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, PA.
² Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville.
³ Division of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California-San Diego, La Jolla.

Abstract

DISCLOSURES: No funding was received for the writing of this commentary. The authors report no conflicts of interest.

MeSH terms

Antibodies, Monoclonal, Humanized / economics
Biomedical Research
Cost-Benefit Analysis
Cyclosporine / economics
Drug Therapy / economics*
Health Equity*
Humans
Immunosuppressive Agents / economics
Insurance Coverage
Insurance, Health
Lupus Nephritis / drug therapy*

Substances

Antibodies, Monoclonal, Humanized
Immunosuppressive Agents
voclosporin
belimumab
Cyclosporine